J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer. 1 mars, vol.136, issue.5, pp.359-386, 2015.

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, vol.67, issue.1, pp.7-30, 2017.

R. Govindan, N. Page, D. Morgensztern, W. Read, R. Tierney et al., Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database, J Clin Oncol, vol.24, issue.28, pp.4539-4583, 2006.

P. Perez-moreno, E. Brambilla, R. Thomas, and J. Soria, Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities, Clin Cancer Res. 1 mai, vol.18, issue.9, pp.2443-51, 2012.

J. R. Molina, Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship, Mayo Clin Proc, p.11

D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith et al., American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update, J Clin Oncol. 15 janv, vol.22, issue.2, pp.330-53, 2003.

N. B. Leighl, Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line, Curr Oncol. juin, vol.19, issue.1, pp.52-60, 2012.

G. A. Masters, S. Temin, C. G. Azzoli, G. Giaccone, S. Baker et al., Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, vol.33, issue.30, pp.3488-515, 2015.

F. Barlesi, J. Mazieres, J. Merlio, D. Debieuvre, J. Mosser et al., Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). The Lancet, avr, vol.387, pp.1415-1441, 2016.

S. J. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami et al., Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
URL : https://hal.archives-ouvertes.fr/hal-01753457

,

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015.

M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, pp.1823-1856, 2016.

R. S. Herbst, P. Baas, D. Kim, E. Felip, J. L. Pérez-gracia et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, The Lancet. avr, vol.387, pp.1540-50, 2016.

A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello et al., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet, vol.389, pp.255-65, 2017.

M. D. Hellmann, T. Ciuleanu, A. Pluzanski, J. S. Lee, G. A. Otterson et al., Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden, N Engl J Med

. Disponible,

C. K. Lee, J. Man, S. Lord, W. Cooper, M. Links et al., Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis, JAMA Oncol. 1 févr, vol.4, issue.2, p.210, 2018.

N. Hanna, D. Johnson, S. Temin, S. Baker, J. Brahmer et al., Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, vol.35, issue.30, pp.3484-515, 2017.

L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, J. Vansteenkiste et al., Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet. 30 avr, vol.387, pp.1837-1883, 2016.

, Trial Compares Pembrolizumab With Chemotherapy as First-Line Treatment of NSCLC With PD-L1 Expression of 1% or More-The ASCO Post

C. J. Langer, S. M. Gadgeel, H. Borghaei, V. A. Papadimitrakopoulou, A. Patnaik et al., Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study, Lancet Oncol, vol.17, issue.11, pp.1497-508, 2016.

M. A. Socinski, R. M. Jotte, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy et al., Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N Engl J Med. 14 juin, vol.378, issue.24, pp.2288-301, 2018.

L. Gandhi, D. Rodríguez-abreu, S. Gadgeel, E. E. Felip, E. et al., Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med. 31 mai, vol.378, issue.22, pp.2078-92, 2018.

J. Malhotra, S. K. Jabbour, and J. Aisner, Current state of immunotherapy for non-small cell lung cancer, Transl Lung Cancer Res. avr, vol.6, issue.2, pp.196-211, 2017.

D. Fujimoto, H. Yoshioka, Y. Kataoka, T. Morimoto, Y. H. Kim et al., Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study, Lung Cancer. mai, vol.119, pp.14-20, 2018.

S. Champiat, L. Dercle, S. Ammari, C. Massard, A. Hollebecque et al., Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by AntiPD-1/PD-L1, Clin Cancer Res. 15 avr, vol.23, issue.8, pp.1920-1928, 2017.

J. M. Michot, C. Bigenwald, S. Champiat, M. Collins, F. Carbonnel et al., Immunerelated adverse events with immune checkpoint blockade: a comprehensive review, Eur J Cancer. févr, vol.54, pp.139-187, 2016.

K. Takada, G. Toyokawa, F. Shoji, T. Okamoto, and Y. Maehara, The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers, Clin Lung Cancer. mars, vol.19, issue.2, pp.120-129, 2018.

E. B. Garon, N. A. Rizvi, R. Hui, N. Leighl, A. S. Balmanoukian et al., Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer, N Engl J Med. 21 mai, vol.372, issue.21, pp.2018-2046, 2015.

M. Khunger, A. V. Hernandez, V. Pasupuleti, S. Rakshit, N. A. Pennell et al., Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis, JCO Precis Oncol, issue.1, pp.1-15, 2017.

J. Mclaughlin, G. Han, K. A. Schalper, D. Carvajal-hausdorf, V. Pelekanou et al., Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer, JAMA Oncol. 1 janv, vol.2, issue.1, pp.46-54, 2016.

D. R. Gandara, S. M. Paul, M. Kowanetz, E. Schleifman, W. Zou et al., Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab, Nat Med, issue.6, 2018.

. Disponible,

N. A. Rizvi, M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov et al., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science. 3 avr, vol.348, issue.6230, pp.124-132, 2015.

E. Brambilla, L. Teuff, G. Marguet, S. Lantuejoul, S. Dunant et al., Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer, J Clin Oncol. 10 avr, vol.34, issue.11, pp.1223-1253, 2016.

D. S. Couraud, Référentiel Rhône Alpes Auvergne, p.57, 2018.

P. Goldstraw, J. Crowley, K. Chansky, D. J. Giroux, P. A. Groome et al., The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, J Thorac Oncol. 1 août, vol.2, issue.8, pp.706-720, 2007.

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Cancer. 1 janv, vol.45, issue.2, pp.228-275, 2009.

J. Remon, N. Vilariño, and N. Reguart, Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions, Cancer Treat Rev. 1 mars, vol.64, pp.21-30, 2018.

O. Abdel-rahman, Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis, Clin Respir J, vol.13, issue.2017

. Disponible,

J. F. Gainor, A. T. Shaw, L. V. Sequist, X. Fu, C. G. Azzoli et al., EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in NonSmall Cell Lung Cancer: A Retrospective Analysis, Clin Cancer Res. 15 sept, vol.22, issue.18, pp.4585-93, 2016.

O. Molinier, B. Besse, F. Barlesi, C. Audigier-valette, S. Friard et al., IFCT 1502-CLINIVO : efficacité et tolérance du nivolumab et du traitement post-nivolumab dans le cancer bronchique non à petites cellules au stade avancé. Une étude en vie réelle dans le cadre de l'ATU nivolumab 2015, Rev Mal Respir. janv, vol.35, p.8, 2018.

S. Popat, A. Ardizzoni, T. Ciuleanu, C. Dols, M. Laktionov et al., 1303PDNivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ?70 years and with poor performance status, Ann Oncol, issue.1, 2017.

K. Sato, H. Akamatsu, E. Murakami, S. Sasaki, K. Kanai et al., Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab, Lung Cancer. janv, vol.115, pp.71-75, 2018.

K. Haratani, H. Hayashi, Y. Chiba, K. Kudo, K. Yonesaka et al., Association of ImmuneRelated Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer, JAMA Oncol. 1 mars, vol.4, issue.3, p.374, 2018.

J. L. Mcquade, C. R. Daniel, K. R. Hess, C. Mak, D. Y. Wang et al., The association of BMI and outcomes in metastatic melanoma: A retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy, Lancet Oncol. mars, vol.19, issue.3, pp.310-332, 2018.

R. J. Canter, C. T. Le, J. Beerthuijzen, and W. J. Murphy, Obesity as an immune-modifying factor in cancer immunotherapy, J Leukoc Biol, vol.15, issue.2018

. Disponible,

B. Routy, L. Chatelier, E. Derosa, L. Duong, C. Alou et al., Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science. 5 janv, vol.359, issue.6371, pp.91-98, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02126484

V. Gopalakrishnan, C. N. Spencer, L. Nezi, A. Reuben, M. C. Andrews et al., Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science. 5 janv, vol.359, issue.6371, pp.97-103, 2018.

V. Matson, J. Fessler, R. Bao, T. Chongsuwat, Y. Zha et al., The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients, Science. 5 janv, vol.359, issue.6371, pp.104-112, 2018.

L. Derosa, B. Routy, G. Kroemer, and L. Zitvogel, The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1, OncoImmunology. 3 juin, vol.7, issue.6, p.1434468, 2018.

A. Sivan, L. Corrales, N. Hubert, J. B. Williams, K. Aquino-michaels et al., Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy, Science, vol.350, issue.6264, pp.1084-1093, 2015.

V. Gopalakrishnan, B. A. Helmink, C. N. Spencer, A. Reuben, and J. A. Wargo, The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy, Cancer Cell. 9 avr, vol.33, issue.4, pp.570-80, 2018.

. Turnbaugth, An obesity-associated gut microbiome with increased capacity for energy harvest | Nature

C. Sanmiguel, A. Gupta, and E. A. Mayer, Gut Microbiome and Obesity: A Plausible Explanation for Obesity, Curr Obes Rep. juin, vol.4, issue.2, pp.250-61, 2015.

O. Castaner, A. Goday, Y. Park, S. Lee, F. Magkos et al., The Gut Microbiome Profile in Obesity: A Systematic Review, Int J Endocrinol, vol.2018, pp.1-9, 2018.

T. F. Nishijima, H. B. Muss, S. S. Shachar, and S. J. Moschos, Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis, Cancer Treat Rev. avr, vol.45, pp.30-37, 2016.

A. Schrock, N. Sharma, N. Peled, J. Bufill, G. Srkalovic et al., 01 Updated Dataset Assessing Tumor Mutation Burden (TMB) as a Biomarker for Response to PD-1/PD-L1 Targeted Therapies in Lung Cancer (LC), J Thorac Oncol. janv, vol.12, issue.1, p.422, 2017.

R. Sun, E. J. Limkin, M. Vakalopoulou, L. Dercle, S. Champiat et al., A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study, Lancet Oncol, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01958243

. Disponible,

J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer. 1 mars, vol.136, issue.5, pp.359-386, 2015.

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, vol.67, issue.1, pp.7-30, 2017.

R. Govindan, N. Page, D. Morgensztern, W. Read, R. Tierney et al., Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database, J Clin Oncol, vol.24, issue.28, pp.4539-4583, 2006.

P. Perez-moreno, E. Brambilla, R. Thomas, and J. Soria, Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities, Clin Cancer Res. 1 mai, vol.18, issue.9, pp.2443-51, 2012.

J. R. Molina, Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship, Mayo Clin Proc, p.11

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015.

R. S. Herbst, P. Baas, D. Kim, E. Felip, J. L. Pérez-gracia et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, The Lancet. avr, vol.387, pp.1540-50, 2016.

A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello et al., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet, vol.389, pp.255-65, 2017.

M. D. Hellmann, T. Ciuleanu, A. Pluzanski, J. S. Lee, G. A. Otterson et al., Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden, N Engl J Med

. Disponible,

S. J. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami et al., Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
URL : https://hal.archives-ouvertes.fr/hal-01753457

,

M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, pp.1823-1856, 2016.

N. Hanna, D. Johnson, S. Temin, S. Baker, J. Brahmer et al., Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, vol.35, issue.30, pp.3484-515, 2017.

S. Gettinger, N. A. Rizvi, L. Q. Chow, H. Borghaei, J. Brahmer et al., Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer, J Clin Oncol. 1 sept, vol.34, issue.25, pp.2980-2987, 2016.

L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, J. Vansteenkiste et al., Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet. 30 avr, vol.387, pp.1837-1883, 2016.

J. Malhotra, S. K. Jabbour, and J. Aisner, Current state of immunotherapy for non-small cell lung cancer, Transl Lung Cancer Res. avr, vol.6, issue.2, pp.196-211, 2017.

E. B. Garon, N. A. Rizvi, R. Hui, N. Leighl, A. S. Balmanoukian et al., Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer, N Engl J Med. 21 mai, vol.372, issue.21, pp.2018-2046, 2015.

S. Champiat, L. Dercle, S. Ammari, C. Massard, A. Hollebecque et al., Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1, Clin Cancer Res. 15 avr, vol.23, issue.8, pp.1920-1928, 2017.

J. M. Michot, C. Bigenwald, S. Champiat, M. Collins, F. Carbonnel et al., Immune-related adverse events with immune checkpoint blockade: a comprehensive review, Eur J Cancer. févr, vol.54, pp.139-187, 2016.

M. Khunger, A. V. Hernandez, V. Pasupuleti, S. Rakshit, N. A. Pennell et al., Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis, JCO Precis Oncol, issue.1, pp.1-15, 2017.

K. Takada, G. Toyokawa, F. Shoji, T. Okamoto, and Y. Maehara, The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers, Clin Lung Cancer. mars, vol.19, issue.2, pp.120-129, 2018.

J. Mclaughlin, G. Han, K. A. Schalper, D. Carvajal-hausdorf, V. Pelekanou et al., Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer, JAMA Oncol. 1 janv, vol.2, issue.1, pp.46-54, 2016.

N. A. Rizvi, M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov et al., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science. 3 avr, vol.348, issue.6230, pp.124-132, 2015.

D. R. Gandara, S. M. Paul, M. Kowanetz, E. Schleifman, W. Zou et al., Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab, Nat Med, issue.6, 2018.

. Disponible,

E. Brambilla, L. Teuff, G. Marguet, S. Lantuejoul, S. Dunant et al., Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer, J Clin Oncol. 10 avr, vol.34, issue.11, pp.1223-1253, 2016.

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline

, Eur J Cancer. 1 janv, vol.45, issue.2, pp.228-275, 2009.

J. Remon, N. Vilariño, and N. Reguart, Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions, Cancer Treat Rev. 1 mars, vol.64, pp.21-30, 2018.

O. Abdel-rahman, Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis, Clin Respir J, vol.13, issue.2017

. Disponible,

J. F. Gainor, A. T. Shaw, L. V. Sequist, X. Fu, C. G. Azzoli et al., EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis, Clin Cancer Res. 15 sept, vol.22, issue.18, pp.4585-93, 2016.

K. Sato, H. Akamatsu, E. Murakami, S. Sasaki, K. Kanai et al., Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab, Lung Cancer. janv, vol.115, pp.71-75, 2018.

K. Haratani, H. Hayashi, Y. Chiba, K. Kudo, K. Yonesaka et al., Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer, JAMA Oncol. 1 mars, vol.4, issue.3, p.374, 2018.

J. L. Mcquade, C. R. Daniel, K. R. Hess, C. Mak, D. Y. Wang et al., The association of BMI and outcomes in metastatic melanoma: A retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy, Lancet Oncol. mars, vol.19, issue.3, pp.310-332, 2018.

R. J. Canter, C. T. Le, J. Beerthuijzen, and W. J. Murphy, Obesity as an immune-modifying factor in cancer immunotherapy, J Leukoc Biol, vol.15, issue.2018

. Disponible,

B. Routy, L. Chatelier, E. Derosa, L. Duong, C. Alou et al., Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science. 5 janv, vol.359, issue.6371, pp.91-98, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01727917

V. Gopalakrishnan, C. N. Spencer, L. Nezi, A. Reuben, M. C. Andrews et al., Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science. 5 janv, vol.359, issue.6371, pp.97-103, 2018.

V. Matson, J. Fessler, R. Bao, T. Chongsuwat, Y. Zha et al., The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients, Science. 05, vol.359, issue.6371, pp.104-112, 2018.

L. Derosa, B. Routy, G. Kroemer, and L. Zitvogel, The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1, OncoImmunology. 3 juin, vol.7, issue.6, p.1434468, 2018.

A. Sivan, L. Corrales, N. Hubert, J. B. Williams, K. Aquino-michaels et al., Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy, Science, vol.350, issue.6264, pp.1084-1093, 2015.

V. Gopalakrishnan, B. A. Helmink, C. N. Spencer, A. Reuben, and J. A. Wargo, The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy, Cancer Cell. 9 avr, vol.33, issue.4, pp.570-80, 2018.

. Turnbaugth, An obesity-associated gut microbiome with increased capacity for energy harvest | Nature

C. Sanmiguel, A. Gupta, and E. A. Mayer, Gut Microbiome and Obesity: A Plausible Explanation for Obesity, Curr Obes Rep. juin, vol.4, issue.2, pp.250-61, 2015.

O. Castaner, A. Goday, Y. Park, S. Lee, F. Magkos et al., The Gut Microbiome Profile in Obesity: A Systematic Review, Int J Endocrinol, vol.2018, pp.1-9, 2018.

T. F. Nishijima, H. B. Muss, S. S. Shachar, and S. J. Moschos, Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis, Cancer Treat Rev. avr, vol.45, pp.30-37, 2016.

C. K. Lee, J. Man, S. Lord, W. Cooper, M. Links et al., Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis, JAMA Oncol. 1 févr, vol.4, issue.2, p.210, 2018.

R. Sun, E. J. Limkin, M. Vakalopoulou, L. Dercle, S. Champiat et al., A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PDL1 immunotherapy: an imaging biomarker, retrospective multicohort study, Lancet Oncol, 2018.

. Disponible,